ML-007C-MA for Acute Schizophrenia Symptoms

ML-007C-MA for Acute Schizophrenia Symptoms
53%42%31%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 42.0%
MapLight Therapeutics ($MPLT)
No stock close$30.30$28.14$25.98May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • MPLT $26.50May 19 • MPLT $27.08May 20 • MPLT $27.81May 21 • MPLT $29.28May 22 • MPLT $28.75May 26 • MPLT $29.46May 27 • MPLT $29.55May 28 • MPLT $29.78

Will this trial show a positive result on change From Baseline to End of Treatment in Positive and Negative Syndrome Scale (PANSS) Total Score?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Primary Completion
8/1/26
Study Completion
8/1/26
Sponsor
MapLight Therapeutics
Ticker
$MPLT
Type
Phase 2
Trial Status
Active Not Recruiting
Trial Size
307
NCT
NCT07038876
Trial Description
This Phase 2 trial tests oral ML-007C-MA in hospitalized adults with acutely worsened schizophrenia, measuring symptom improvement after 5 weeks.